ArticleCell death discovery2026
The role and mechanism of tubulin folding cofactor B in glioblastoma migration.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in the central nervous system, characterized by high invasiveness, incidence, and mortality. Tubulin folding cofactor B (TBCB) is a microtubule-associated regulator implicated in microtubule plus-end organization and related structural features; however, its role and underlying mechanisms in GBM remain unclear. This study aimed to elucidate the function and mechanisms of TBCB in GBM cell proliferation and migration. Analyses of public databases (GEO, TCGA, CGGA) and clinical GBM specimens revealed that TBCB was significantly upregulated in GBM compared with normal controls, with higher expression correlating with higher WHO grades and poor prognosis. Functionally, TBCB knockdown in U87 and U251 cells significantly inhibited proliferation and migration (assessed by EdU, cell counting, Transwell and wound-healing assays) and impaired cell process formation; consistently, in vivo experiments using orthotopic intracranial xenograft models confirmed that TBCB knockdown suppressed tumor growth and prolonged survival. Mechanistically, reciprocal Co-IP/IF supported association of TBCB with both EB1 and EB3, indicating that TBCB acts as a functional partner of the microtubule plus-end tracking proteins ( + TIPs) EB1 and EB3, co-localizing at cell process tips and being associated with microtubule plus-end organization/comet-like features. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified the MAPK pathway as a key signaling pathway associated with TBCB; Western blotting showed that TBCB knockdown reduced the p-ERK/ERK ratio, and pharmacological modulation with the ERK agonist TPA and the MEK inhibitor U0126 further indicated that ERK-pathway perturbation regulates TBCB in a time-dependent and nonlinear manner in GBM cells. Collectively, these findings indicate that TBCB promotes GBM cell proliferation and migration through EB1/EB3-associated microtubule plus-end organization and is functionally coupled to the ERK-MAPK pathway in a time-dependent and nonlinear manner, suggesting that TBCB is a candidate regulator of GBM progression that warrants further translational validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.